Clinical Trial Update: A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) [Phase 3]

View source ↗

Summary

A Phase 3 safety extension study in erythropoietic protoporphyria has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria

Drugs mentioned

• Clinuvel Pharmaceuticals Limited

Snippet

Sponsor: Clinuvel Pharmaceuticals Limited | Conditions: Erythropoietic Protoporphyria | Phase 3 | Status: COMPLETED | Results posted: 2020-11-02